1
|
Montori M, Martini F, DE Blasio F, Buono T, Quatraccioni C, Guardati P, Calzolari M, Rossi C, Bendia E, Menzo S, Valenza C, Pellicano R, Maroni L, Benedetti A. Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. Minerva Gastroenterol (Torino) 2023; 69:268-276. [PMID: 36255283 DOI: 10.23736/s2724-5985.22.03134-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
BACKGROUND Inflammatory bowel disease (IBD) patients on biological therapy are receiving vaccines against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). However, it is unclear if IBD therapy could influence the response to this vaccine. In a case-control study, we assessed the antibody profiling after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy. METHODS We analyzed seroprevalence and antibody titer, after 14 weeks from the first BNT162b2 vaccine dose, in IBD patients on biological therapy and health care workers (HCWs). In IBD patients, medical history and disease data were recorded. RESULTS Eighty-two subjects were enrolled in this study. Among them, 40 were IBD patients on biological therapy and 42 were HCWs. All subjects developed an IgG anti-Spike antibody titer above the cut-off. IBD patients on biological therapy developed a lower antibody titer than HCWs (P<0.00001). No differences were reported in patients who received at least one dose of the vaccine within a period of 7 days from the last biological drug administration, compared to all other IBD patients. A difference was found between patients who were on concomitant immunosuppressive therapy and patients on sole biological therapy (P=0.0287). Patients with presence of any sign of disease activity (clinical, endoscopic or laboratory) showed a higher development of antibody titer compared to those in complete disease remission (P=0.0468). CONCLUSIONS Our data indicate that in IBD patients, treatment with biological therapies do not affect the seroprevalence but leads to a lower antibody titer development after anti-SARS-CoV-2 BNT162b2 vaccine.
Collapse
Affiliation(s)
- Michele Montori
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy -
| | - Francesco Martini
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Federico DE Blasio
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Tiziana Buono
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Claudia Quatraccioni
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Paola Guardati
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Manuela Calzolari
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Chiara Rossi
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Emanuele Bendia
- Department of Digestive System Diseases, Digestive Endoscopy and Chronic Inflammatory Bowel Diseases, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Stefano Menzo
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Carmine Valenza
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy
| | | | - Luca Maroni
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Antonio Benedetti
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| |
Collapse
|
2
|
Lenti MV, Aronico N, Bianchi PI, D'Agate CC, Neri M, Volta U, Mumolo MG, Astegiano M, Calabrò AS, Zingone F, Latella G, Di Sario A, Carroccio A, Ciacci C, Luzza F, Bagnato C, Fantini MC, Elli L, Cammarota G, Gasbarrini A, Portincasa P, Latorre MA, Petrucci C, Quatraccioni C, Iannelli C, Vecchione N, Rossi CM, Broglio G, Ianiro G, Marsilio I, Bibbò S, Marinoni B, Tomaselli D, Abenavoli L, Pilia R, Santacroce G, Lynch E, Carrieri A, Mansueto P, Gabba M, Alunno G, Rossi C, Onnis F, Efthymakis K, Cesaro N, Vernero M, Baiano Svizzero F, Semeraro FP, Silano M, Vanoli A, Klersy C, Corazza GR, Di Sabatino A. Diagnostic delay in adult coeliac disease: An Italian multicentre study. Dig Liver Dis 2022; 55:743-750. [PMID: 36567177 DOI: 10.1016/j.dld.2022.11.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 11/29/2022] [Accepted: 11/29/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND There are few data regarding the diagnostic delay and its predisposing factors in coeliac disease (CD). AIMS To investigate the overall, the patient-dependant, and the physician-dependant diagnostic delays in CD. METHODS CD adult patients were retrospectively enroled at 19 Italian CD outpatient clinics (2011-2021). Overall, patient-dependant, and physician-dependant diagnostic delays were assessed. Extreme diagnostic, i.e., lying above the third quartile of our population, was also analysed. Multivariable regression models for factors affecting the delay were fitted. RESULTS Overall, 2362 CD patients (median age at diagnosis 38 years, IQR 27-46; M:F ratio=1:3) were included. The median overall diagnostic delay was 8 months (IQR 5-14), while patient- and physician-dependant delays were 3 (IQR 2-6) and 4 (IQR 2-6) months, respectively. Previous misdiagnosis was associated with greater physician-dependant (1.076, p = 0.005) and overall (0.659, p = 0.001) diagnostic delays. Neurological symptoms (odds ratio 2.311, p = 0.005) and a previous misdiagnosis (coefficient 9.807, p = 0.000) were associated with a greater extreme physician-dependant delay. Gastrointestinal symptoms (OR 1.880, p = 0.004), neurological symptoms (OR 2.313, p = 0.042), and previous misdiagnosis (OR 4.265, p = 0.000) were associated with increased extreme overall diagnostic delay. CONCLUSION We identified some factors that hamper CD diagnosis. A proper screening strategy for CD should be implemented.
Collapse
Affiliation(s)
- Marco Vincenzo Lenti
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Nicola Aronico
- First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Paola Ilaria Bianchi
- First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Carmela Cinzia D'Agate
- Department of Gastroenterology and Endoscopy, University Hospital "G. Rodolico", Catania, Italy
| | - Matteo Neri
- Department of Medicine and Ageing Sciences, 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy
| | - Umberto Volta
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Maria Gloria Mumolo
- Department of General Surgery and Gastroenterology, Pisa University Hospital, Pisa, Italy
| | - Marco Astegiano
- SC Gastroenterologia AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | - Antonino Salvatore Calabrò
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence, Florence, Italy
| | - Fabiana Zingone
- Department of Surgery, Oncology and Gastroenterology, University of Padua, and Gastroenterology Unit, Azienda Ospedale Università, Padova, Italy
| | - Giovanni Latella
- Gastroenterology, Hepatology and Nutrition Division, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Antonio Di Sario
- Department of Gastroenterology and Transplantation, Polytechnic Marche University, Ancona, Italy
| | - Antonio Carroccio
- Internal Medicine Unit, "V. Cervello Hospital", University of Palermo, Palermo, Italy
| | - Carolina Ciacci
- Department of Medicine and Surgery, Gastroenterology Unit, University of Salerno, Salerno, Italy
| | - Francesco Luzza
- Department of Health Sciences, Magna Græcia University, Catanzaro, Italy
| | - Carmela Bagnato
- Clinical Nutrition Unit, Madonna delle Grazie Hospital, Matera, Italy
| | | | - Luca Elli
- Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Giovanni Cammarota
- Digestive Disease Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Medicina Interna e Gastroenterologia, Università Cattolica Del Sacro Cuore, Rome, Italy
| | - Antonio Gasbarrini
- Digestive Disease Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Medicina Interna e Gastroenterologia, Università Cattolica Del Sacro Cuore, Rome, Italy
| | - Piero Portincasa
- Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Clinica Medica "A. Murri", Bari, Italy
| | - Mario Andrea Latorre
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Clarissa Petrucci
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Claudia Quatraccioni
- Gastroenterology, Hepatology and Nutrition Division, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Chiara Iannelli
- Department of Health Sciences, Magna Græcia University, Catanzaro, Italy
| | - Nicoletta Vecchione
- Department of Gastroenterology and Endoscopy, University Hospital "G. Rodolico", Catania, Italy
| | - Carlo Maria Rossi
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Giacomo Broglio
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Gianluca Ianiro
- Digestive Disease Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Medicina Interna e Gastroenterologia, Università Cattolica Del Sacro Cuore, Rome, Italy
| | - Ilaria Marsilio
- Department of Surgery, Oncology and Gastroenterology, University of Padua, and Gastroenterology Unit, Azienda Ospedale Università, Padova, Italy
| | - Stefano Bibbò
- Digestive Disease Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Medicina Interna e Gastroenterologia, Università Cattolica Del Sacro Cuore, Rome, Italy
| | - Beatrice Marinoni
- Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | | | - Ludovico Abenavoli
- Department of Health Sciences, Magna Græcia University, Catanzaro, Italy
| | - Riccardo Pilia
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy
| | - Giovanni Santacroce
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Erica Lynch
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence, Florence, Italy
| | - Antonella Carrieri
- Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Clinica Medica "A. Murri", Bari, Italy
| | - Pasquale Mansueto
- Internal Medicine Unit, "V. Cervello Hospital", University of Palermo, Palermo, Italy
| | - Margherita Gabba
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Giacomo Alunno
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Chiara Rossi
- Department of Gastroenterology and Transplantation, Polytechnic Marche University, Ancona, Italy
| | - Francesca Onnis
- Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
| | - Konstantinos Efthymakis
- Department of Medicine and Ageing Sciences, 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy
| | - Nicola Cesaro
- Gastroenterology, Hepatology and Nutrition Division, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Marta Vernero
- SC Gastroenterologia AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | | | | | | | - Alessandro Vanoli
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and IRCCS San Matteo Hospital Foundation, Pavia, Italy
| | - Catherine Klersy
- Clinical Epidemiology and Biometry Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Gino Roberto Corazza
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Antonio Di Sabatino
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| |
Collapse
|
3
|
Balducci D, Quatraccioni C, Benedetti A, Marzioni M, Maroni L. Gastrointestinal disorders as immune-related adverse events. Exploration of Targeted Anti-tumor Therapy 2021; 2:174-186. [PMID: 36046145 PMCID: PMC9400751 DOI: 10.37349/etat.2021.00039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 02/23/2021] [Indexed: 11/19/2022] Open
Abstract
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results and an increase in survival rates. However, immune-related adverse events (irAEs) are frequent and often require special care. IrAEs may affect all the organs, but they are most commonly seen in skin, lungs, endocrine glands and in the gastrointestinal tract where small bowel, colon, the liver and/or the pancreas can be involved. Despite being usually mild and self-resolving, irAEs may present in severe and life-threatening forms, causing the withdrawal of anti-cancer therapy. IrAEs, therefore, represent a challenging condition to manage that often requires the cooperation between the oncologists and the gastroenterologists in order to identify and treat them adequately.
Collapse
Affiliation(s)
- Daniele Balducci
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy
| | - Claudia Quatraccioni
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy
| | - Antonio Benedetti
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy
| | - Marco Marzioni
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy
| | - Luca Maroni
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy
| |
Collapse
|